0853 GMT - GSK's results look solid with increased sales and earnings and a maintained 2025 forecast, Barclays analysts say in a note. The British drugmaker's sales came in line with Barclays's estimates and beat a company-compiled consensus. Its vaccine business declined but that was expected, the analysts note. Barclays now expects investors to focus on U.S. healthcare policy, with concerns on headlines regarding vaccines as well as HIV prevention programs, they add. Shares are up 2.8% at 1,472.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 04:54 ET (08:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.